Back to News
Market Impact: 0.3
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst EstimatesCompany Fundamentals
Beam Therapeutics reported a quarterly loss of $1.28 per share, 11 cents wider than the Zacks Consensus Estimate of a $1.17 loss. The loss also widened from $1.10 per share a year earlier.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
BEAM-0.55
More News
- Beam earnings missed by $0.13, revenue fell short of estimates
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history